Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03095781 · ClinicalTrials.gov registry record · Phase 1
Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer
A Phase 1 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
NCT03095781 is a Phase 1 study that has completed, run by Emory University. The registered enrollment target is 47 participants.
The verdict
NCT03095781, a Phase 1 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
Study Summary
This phase Ib trial studies the side effects and best dose of Hsp90 inhibitor XL888 when given together with pembrolizumab in treating patients with advanced gastrointestinal cancer that has spread to other places in the body. XL888 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as pembrolizumab, may block tumor growth in different ways by targeting certain cells. Giving XL888 with pembrolizumab may work better in treating patients with gastrointestinal cancer.
Interventions
- BIOLOGICAL Pembrolizumab
- DRUG XL888
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2017-07-07 |
| Est. Completion | 2021-06-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03095781
The ClinicalTrials.gov registry entry for NCT03095781 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03095781 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03095781 about?
NCT03095781 is a clinical study titled "Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer". This phase Ib trial studies the side effects and best dose of Hsp90 inhibitor XL888 when given together with pembrolizumab in treating patients with advanced gastrointestinal cancer that has spread to other places in the body. XL888 may stop the growth of tumor cells by blocking some of the enzymes ...
What is the current status of trial NCT03095781?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2017-07-07. Estimated completion is 2021-06-10.
What interventions are being tested in trial NCT03095781?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), XL888 (DRUG).
Who is sponsoring clinical trial NCT03095781?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.